9 7 0 5 2
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
肿瘤免疫检查点抑制剂疗效预测标志物
Authors Tong M, Wang J, He W, Wang Y, Pan H, Li D, Zhang H
Received 10 July 2018
Accepted for publication 20 August 2018
Published 11 October 2018 Volume 2018:10 Pages 4501—4507
DOI https://doi.org/10.2147/CMAR.S179680
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr Beicheng Sun
摘要：以程序性死亡受体 1（PD-1）／程序性死亡受体配体 1（PD-L1）为代表的免疫检查点抑制剂的发展为晚期肿瘤患者的治疗提供了新的希望。然而，尚无有效的疗效预测标志物在很大程度上限制了免疫检查点抑制剂的临床应用。本文结合国内外近期相关研究和临床试验，讨论在免疫治疗过程中，PD-L1 表达水平作为免疫治疗预测标志物的现状和未来，并探讨肿瘤突变负荷（TMB）、肿瘤侵润性淋巴细胞（TILs）、肿瘤细胞基因表达谱（GEP）以及外周血标记物等作为新型免疫治疗疗效预测标志物的可能性。并就肿瘤免疫治疗疗效预测标志物这一热点话题做简要综述。
关键词：免疫治疗、免疫检查点抑制剂、疗效预测标志物
